Verified source report
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
What happened
According to STAT’s source item, STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug, Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Context
The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-06-06T18:32:27+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.
Source links
- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drugSTAT - 2026-06-06T18:32:27+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.